| Phase 11 trial |
|
Phase 1
|
NCT04972942 |
May 2023 → Sep 2027 expected |
T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma |
New York Medical College |
Recruiting
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT06015724 |
Jan 2024 → Jun 2027 expected |
non-small cell lung carcinoma, pancreatic ductal adenocarcinoma |
Georgetown University |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04065789 |
May 2018 → Aug 2021 |
plasma cell myeloma |
Tel-Aviv Sourasky Medical Center |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02977494 |
Jun 2016 → Jun 2021 |
plasma cell myeloma |
University Medical Center Hamburg-Eppendorf |
Completed
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT07072585 |
Aug 2026 → Sep 2035 expected |
T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma |
Children's Oncology Group |
Not yet recruiting
|
No outcome recorded
|
| Phase 41 trial |
|
Phase 4
|
NCT03768960 |
Jun 2019 → Jul 2022 |
plasma cell myeloma |
Johnson & Johnson Private Limited |
Completed
|
No outcome recorded
|
| Phase not applicable1 trial |
| — |
NCT07015021 |
Jun 2025 → Sep 2026 expected |
plasma cell myeloma |
The First Affiliated Hospital of Soochow University |
Not yet recruiting
|
No outcome recorded
|